Neoadjuvant Therapy With Cabozantinib as a Bridge to Liver Transplantation in Patients With Hepatocellular Carcinoma (HCC): A Case Report.

Autor:	Bhardwaj H; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, United States., Fritze D; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, United States., Mais D; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, United States., Kadaba V; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, United States., Arora SP; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in transplantation [Front Transplant] 2022 May 06; Vol. 1, pp. 863086. Date of Electronic Publication: 2022 May 06 (Print Publication: 2022).
DOI:	10.3389/frtra.2022.863086
Abstrakt:	Liver transplant (LT) is the treatment of choice for unresectable, localized hepatocellular carcinoma (HCC). However, transplant is not recommended for patients who have extensive tumor growth and do not meet specific criteria. For these cases, "bridging" therapies are often used to either downstage or prevent tumor progression while patients are on the transplant list. Various pre-transplant therapies have been used, including transarterial chemoembolization, radiofrequency ablation, and systemic therapies. Sorafenib is a well-known systemic agent used for HCC, but research is limited on its use as well as the use of newer agents as bridging therapy. Prospective studies are also lacking. We discuss cases of two patients diagnosed with HCC and treated systemically with cabozantinib prior to transplant without treatment-related complications. This suggests that cabozantinib could be safely used after sorafenib therapy to control disease related to HCC while awaiting liver transplantation. Competing Interests: SA reports that she is on the speaker's bureau for Exelixis, Bristol-Meyers Squibb, and Bayer and advisory board for AstraZeneca and QED Therapeutics/Helsinn, and SA's institution has received research funding from Beigene, Faron, Halozyme, Ipsen, TerSera Therapeutics, Tvardi, and Caris Life Sciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Bhardwaj, Fritze, Mais, Kadaba and Arora.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu